Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217345 · ClinicalTrials.gov registry record · Phase 2
Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT02217345: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT02217345 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 131 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02217345, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. NAFLD is expected to be the most common indication for liver transplantation by the year 2020. We hypothesize that growth hormone (GH) replacement will decrease intrahepatic lipid accumulation as quantified by 1H magnetic resonance spectroscopy (1H-MRS).
Interventions
- DRUG Placebo
- DRUG Growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2021-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02217345
The ClinicalTrials.gov registry entry for NCT02217345 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02217345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02217345 about?
NCT02217345 is a clinical study titled "Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease". Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form o...
What is the current status of trial NCT02217345?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2017-06-02. Estimated completion is 2021-09-13.
What interventions are being tested in trial NCT02217345?
The interventions under investigation include: Placebo (DRUG), Growth hormone (DRUG).
Who is sponsoring clinical trial NCT02217345?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.